Lymphoma Translocation Protein 1} inhibitor program. Through this partnership, AbbVie gains exclusive global rights to develop and commercialize Lupin's MALTl inhibitors. MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of hematological cancers, many with limited current treatment options.Pharma major Lupin and global biopharmaceutical company AbbVie Inc., announced that AbbVie has licensed Lupin's MALTl (Mucosa-Associated Lymphoid Tissue

Nilesh Gupta, Managing Director, Lupin, said, "Delivering on new drugs was a key element of Dr. Deshbandhu Gupta's vision. We are extremely proud of being able to realize his vision to bring new t reatments to patients in need. We are very pleased to partner with AbbVie who share a commitment to deliver high quality medicines in areas that lack approved treatment and have a dire medical need. Their proven success in rapidly commercializing new targeted oncology treatments made them our partner of choice for this program."